Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.66 |
| ▸ | KDR | P35968 | 20/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | MST1R | Q04912 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.50 |
| ▸ | FPR3 | P25089 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
| ▸ | SMO | Q99835 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300876 | 0.94 | MET (0.59) | METKDRFLT1FLT4MST1R | |
| SCHEMBL4300913 | 0.94 | MET (0.64) | METKDRFLT1FLT4MST1R | |
| SCHEMBL4296630 | 0.90 | MET (0.56) | METKDRFLT1FLT4MST1R | |
| SCHEMBL4300690 | 0.87 | MET (0.52) | METKDRFLT1FLT4MST1R | |
| SCHEMBL4298150 | 0.85 | MET (0.51) | METKDRFLT1FLT4MST1R | |
| SCHEMBL4294359 | 0.85 | MET (0.52) | METKDRFLT1FLT4MST1R | |
| SCHEMBL3574199 | 0.84 | MET (0.75) | METKDRFLT1FLT4AURKA | |
| SCHEMBL5173908 | 0.84 | MET (0.53) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL4302120 | 0.82 | MET (0.53) | METKDRFLT1FLT4MST1R | |
| SCHEMBL3560490 | 0.80 | MET (0.86) | METKDRFLT1FLT4MST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | claimed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1870414-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | Kirin Pharma Kabushiki Kaisha (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | MET 1/4885KDR 39/4885FLT1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.